|
1
|
Scott DL, Wolfe F and Huizinga TW:
Rheumatoid arthritis. Lancet. 376:1094–1108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McInnes IB and Schett G: The pathogenesis
of rheumatoid arthritis. New Engl J Med. 365:2205–2219. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smolen JS, Emery P, Fleischmann R, van
Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L,
Arora V and Kavanaugh A: Adjustment of therapy in rheumatoid
arthritis on the basis of achievement of stable low disease
activity with adalimumab plus methotrexate or methotrexate alone:
The randomised controlled OPTIMA trial. Lancet. 383:321–332. 2014.
View Article : Google Scholar
|
|
4
|
Sangha O: Epidemiology of rheumatic
diseases. Rheumatology (Oxford). 39(Suppl 2): 3–12. 2000.
View Article : Google Scholar
|
|
5
|
Li R, Sun J, Ren LM, Wang HY, Liu WH,
Zhang XW, Chen S, Mu R, He J, Zhao Y, et al: Epidemiology of eight
common rheumatic diseases in China: A large-scale cross-sectional
survey in Beijing. Rheumatology (Oxford). 51:721–729. 2012.
View Article : Google Scholar
|
|
6
|
Cross M, Smith E, Hoy D, Carmona L, Wolfe
F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, et al: The
global burden of rheumatoid arthritis: Estimates from the global
burden of disease 2010 study. Ann Rheum Dis. 73:1316–1322. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uhlig T, Moe RH and Kvien TK: The burden
of disease in rheumatoid arthritis. Pharmacoeconomics. 32:841–851.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hyrich KL, Symmons DP, Watson KD and
Silman AJ; British Society for Rheumatology Biologics Register:
Comparison of the response to infliximab or etanercept monotherapy
with the response to cotherapy with methotrexate or another
disease-modifying anti-rheumatic drug in patients with rheumatoid
arthritis: Results from the British Society for Rheumatology
Biologics Register. Arthritis Rheum. 54:1786–1794. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Listing J, Strangfeld A, Rau R, Kekow J,
Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR and Zink A:
Clinical and functional remission: Even though biologics are
superior to conventional DMARDs overall success rates remain
low–results from RABBIT, the German biologics register. Arthritis
Res Ther. 8:R662006. View
Article : Google Scholar
|
|
10
|
Gonzalez-Rey E, Gonzalez MA, Varela N,
O'Valle F, Hernandez-Cortes P, Rico L, Büscher D and Delgado M:
Human adipose-derived mesenchymal stem cells reduce inflammatory
and T cell responses and induce regulatory T cells in vitro in
rheumatoid arthritis. Ann Rheum Dis. 69:241–248. 2010. View Article : Google Scholar
|
|
11
|
Sun L, Akiyama K, Zhang H, Yamaza T, Hou
Y, Zhao S, Xu T, Le A and Shi S: Mesenchymal stem cell
transplantation reverses multiorgan dysfunction in systemic lupus
erythematosus mice and humans. Stem Cells. 27:1421–1432. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Bari C: Are mesenchymal stem cells in
rheumatoid arthritis the good or bad guys? Arthritis Res Ther.
17:1132015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Papadopoulou A, Yiangou M, Athanasiou E,
Zogas N, Kaloyannidis P, Batsis I, Fassas A, Anagnostopoulos A and
Yannaki E: Mesenchymal stem cells are conditionally therapeutic in
preclinical models of rheumatoid arthritis. Ann Rheum Dis.
71:1733–1740. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stolzing A, Jones E, McGonagle D and Scutt
A: Age-related changes in human bone marrow-derived mesenchymal
stem cells: Consequences for cell therapies. Mech Ageing Dev.
129:163–173. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baksh D, Yao R and Tuan RS: Comparison of
proliferative and multilineage differentiation potential of human
mesenchymal stem cells derived from umbilical cord and bone marrow.
Stem Cells. 25:1384–1392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weiss ML, Anderson C, Medicetty S,
Seshareddy KB, Weiss RJ, VanderWerff I, Troyer D and McIntosh KR:
Immune properties of human umbilical cord Wharton's jelly-derived
cells. Stem Cells. 26:2865–2874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Mu R, Wang S, Long L, Liu X, Li R,
Sun J, Guo J, Zhang X, Guo J, et al: Therapeutic potential of human
umbilical cord mesenchymal stem cells in the treatment of
rheumatoid arthritis. Arthritis Res Ther. 12:R2102010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X,
Gong W, Han ZB, Xu ZS, Lu YX, Liu D, et al: Isolation and
characterization of human umbilical cord mesenchymal stem cells
with hematopoiesis-supportive function and other potentials.
Haematologica. 91:1017–1026. 2006.PubMed/NCBI
|
|
19
|
Cao Y, Sun Z, Liao L, Meng Y, Han Q and
Zhao RC: Human adipose tissue-derived stem cells differentiate into
endothelial cells in vitro and improve postnatal neovascularization
in vivo. Biochem Biophys Res Commun. 332:370–379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arnett FC, Edworthy SM, Bloch DA, McShane
DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS,
et al: The American Rheumatism Association 1987 revised criteria
for the classification of rheumatoid arthritis. Arthritis Rheum.
31:315–324. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho CS, Cho ML, Min SY, Kim WU, Min DJ,
Lee SS, Park SH, Choe J and Kim HY: CD40 engagement on synovial
fibroblast up-regulates production of vascular endothelial growth
factor. J Immunol. 164:5055–5061. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Moelants EA, Mortier A, Van Damme J and
Proost P: Regulation of TNF-α with a focus on rheumatoid arthritis.
Immunol Cell Biol. 91:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brennan FM and McInnes IB: Evidence that
cytokines play a role in rheumatoid arthritis. J Clin Invest.
118:3537–3545. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kokkonen H, Söderström I, Rocklöv J,
Hallmans G, Lejon K and Rantapää Dahlqvist S: Up-regulation of
cytokines and chemokines predates the onset of rheumatoid
arthritis. Arthritis Rheum. 62:383–391. 2010.PubMed/NCBI
|
|
26
|
Kasperkovitz PV, Timmer TC, Smeets TJ,
Verbeet NL, Tak PP, van Baarsen LG, Baltus B, Huizinga TW,
Pieterman E, Fero M, et al: Fibroblast-like synoviocytes derived
from patients with rheumatoid arthritis show the imprint of
synovial tissue heterogeneity: Evidence of a link between an
increased myofibroblast-like phenotype and high-inflammation
synovitis. Arthritis Rheum. 52:430–441. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Noss EH and Brenner MB: The role and
therapeutic implications of fibroblast-like synoviocytes in
inflammation and cartilage erosion in rheumatoid arthritis. Immunol
Rev. 223:252–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dass S, Vital EM and Emery P: Rituximab:
Novel B-cell depletion therapy for the treatment of rheumatoid
arthritis. Opin Pharmacother. 7:2559–2570. 2006. View Article : Google Scholar
|
|
29
|
Colmegna I, Ohata BR and Menard HA:
Current understanding of rheumatoid arthritis therapy. Clin
Pharmacol Ther. 91:607–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giles JT, Bartlett SJ, Gelber AC, Nanda S,
Fontaine K, Ruffing V and Bathon JM: Tumor necrosis factor
inhibitor therapy and risk of serious postoperative orthopedic
infection in rheumatoid arthritis. Arthritis Rheum. 55:333–337.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moreland LW, Schiff MH, Baumgartner SW,
Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC,
Furst DE, Mease PJ, et al: Etanercept therapy in rheumatoid
arthritis. A randomized, controlled trial. Ann Intern Med.
130:478–486. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Augello A, Tasso R, Negrini SM, Cancedda R
and Pennesi G: Cell therapy using allogeneic bone marrow
mesenchymal stem cells prevents tissue damage in collagen-induced
arthritis. Arthritis Rheum. 56:1175–1186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Bari C, Dell'Accio F, Karystinou A,
Guillot PV, Fisk NM, Jones EA, McGonagle D, Khan IM, Archer CW,
Mitsiadis TA, et al: A biomarker-based mathematical model to
predict bone-forming potency of human synovial and periosteal
mesenchymal stem cells. Arthritis Rheum. 58:240–250. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kastrinaki MC, Sidiropoulos P, Roche S,
Ringe J, Lehmann S, Kritikos H, Vlahava VM, Delorme B, Eliopoulos
GD, Jorgensen C, et al: Functional, molecular and proteomic
characterisation of bone marrow mesenchymal stem cells in
rheumatoid arthritis. Ann Rheum Dis. 67:741–749. 2008. View Article : Google Scholar
|
|
35
|
Catterall JB, Carrère S, Koshy PJ, Degnan
BA, Shingleton WD, Brinckerhoff CE, Rutter J, Cawston TE and Rowan
AD: Synergistic induction of matrix metalloproteinase 1 by
interleukin-1alpha and oncostatin M in human chondrocytes involves
signal transducer and activator of transcription and activator
protein 1 transcription factors via a novel mechanism. Arthritis
Rheum. 44:2296–2310. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hötten G, Neidhardt H, Jacobowsky B and
Pohl J: Cloning and expression of recombinant human
growth/differentiation factor 5. Biochem Biophys Res Commun.
204:646–652. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bobacz K, Gruber R, Soleiman A, Graninger
WB, Luyten FP and Erlacher L: Cartilage-derived morphogenetic
protein-1 and-2 are endogenously expressed in healthy and
osteoarthritic human articular chondrocytes and stimulate matrix
synthesis. Osteoarthritis Cartilage. 10:394–401. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morotome Y, Goseki-Sone M, Ishikawa I and
Oida S: Gene expression of growth and differentiation factors-5,
-6, and -7 in developing bovine tooth at the root forming stage.
Biochem Biophys Res Commun. 244:85–90. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hötten GC, Matsumoto T, Kimura M, Bechtold
RF, Kron R, Ohara T, Tanaka H, Satoh Y, Okazaki M, Shirai T, et al:
Recombinant human growth/differentiation factor 5 stimulates
mesenchyme aggregation and chondrogenesis responsible for the
skeletal development of limbs. Growth Factors. 13:65–74. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu FL, Lin LH, Sytwu HK and Chang DM:
GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated
chondrogenic differentiation in human rheumatoid fibroblast-like
synoviocytes. Exp Mol Pathol. 88:163–170. 2010. View Article : Google Scholar
|
